Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia

This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.

NCT Number	NCT07495943
Lead Sponsor	Haydarpasa Numune Training and Research Hospital Collaborators: Almediko Saglik Urunleri Turizm Gida Sanayi ve Ticaret Limited Sirketi
Conditions	Fibromyalgia Syndrome, Fibromyalgia
Enrollment	200 participants
Start Date	2026-05-04
Primary Completion	2027-05-04 (estimated)
Study Completion	2027-05-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-01